SCHEMBL3380949

SCHEMBL3380949

Cc1cccc(Nc2cc(Cl)nc(CC(O)=S)n2)c1C

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARA Q07869 13/20 0.67
PPARG P37231 12/20 0.57
RXRA P19793 7/20 0.57
RXRB P28702 6/20 0.57
PPARD Q03181 4/20 0.57
RXRG P48443 4/20 0.57
KDM4E B2RXH2 2/20 0.57
KMT2A Q03164 2/20 0.57
MEN1 O00255 1/20 0.57
ABCC4 O15439 1/20 0.57
ABCB11 O95342 1/20 0.57
ALDH1A1 P00352 1/20 0.57
CYP3A4 P08684 1/20 0.57
CYP2D6 P10635 1/20 0.57
HPGD P15428 1/20 0.57
ALOX15 P16050 1/20 0.57
SMN1; SMN2 Q16637 1/20 0.57
ALOX5 P09917 3/20 0.49
PTGES O14684 4/20 0.48
LMNA P02545 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8015983 0.91 PPARA (0.57) PPARAPPARGRXRARXRBPPARD
SCHEMBL4433116 0.87 PPARA (0.57) PPARAPPARGRXRARXRBPPARD
SCHEMBL3512239 0.84 PPARA (0.69) PPARAPPARGRXRARXRBPPARD
SCHEMBL10997581 0.82 PPARA (0.47) PPARAPPARGRXRARXRBPPARD
SCHEMBL11001933 0.79 NPC1 (0.52) PPARAPPARGRXRARXRBPPARD
SCHEMBL10997703 0.77 PPARA (0.58) PPARAPPARGRXRARXRBPPARD
SCHEMBL7926723 0.77 PPARA (0.51) PPARAPPARGRXRARXRBPPARD
SCHEMBL15062964 0.75 PPARA (0.56) PPARAPPARGRXRARXRBPPARD
Acetic Acid SCHEMBL3773388 0.74 PPARA (0.61) PPARAPPARGRXRARXRBPPARD
Aronixil SCHEMBL2732727 0.74 PPARA (0.64) PPARAPPARGRXRARXRBPPARD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3841097-B1 2,6-BIS(((1H-BENZO[D]IMIDAZOL-2-YL)THIO)METHYL)PYRIDINE AND N2,N6-DIBENZYLPYRIDINE-2,6-DICARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS PHOSPHOINOSITIDE 3-KINASE (PI3K) INHIBITORS FOR TREATING CANCER BIOMEDICAL RES FOUNDATION OF THE ACADEMY OF ATHENS BRFAA (GR) 2026-05-20 EP claimed
EP-3319965-B1 NOVEL COMPOUNDS FOR USE IN TREATING OR PREVENTING CANCEROUS DISEASES BIOMEDICAL RES FOUNDATION OF THE ACADEMY OF ATHENS (GR) 2022-05-04 EP claimed
CN-113272294-A 2, 6-bis (((1H-benzo [ D ] imidazol-2-yl) thio) methyl) pyridine and N2, N6-dibenzylpyridine-2, 6-dicarboxamide derivatives and related compounds as phosphoinositide 3-kinase (PI3K) inhibitors for the treatment of cancer 雅典学院生物医学研究基金会 2021-08-17 CN claimed
US-20210246120-A1 METHOD OF PREPARATION AND USE OF PHOSPHOINOSITIDE 3-KINASE INHIBITORS IN TREATING CANCER FOUNDATION FOR RESEARCH AND TECHNOLOGY HELLAS (FORTH) (GR) 2021-08-12 US claimed
EP-3841097-A1 2,6-BIS(((1H-BENZO[D]IMIDAZOL-2-YL)THIO)METHYL)PYRIDINE AND N2,N6-DIBENZYLPYRIDINE-2,6-DICARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS PHOSPHOINOSITIDE 3-KINASE (PI3K) INHIBITORS FOR TREATING CANCER Biomedical Research Foundation of the Academy of Athens (GR) 2021-06-30 EP claimed
WO-2020039097-A1 2,6-BIS(((1H-BENZO[D]IMIDAZOL-2-YL)THIO)METHYL)PYRIDINE AND N2,N6-DIBENZYLPYRIDINE-2,6-DICARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS PHOSPHOINOSITIDE 3-KINASE (PI3K) INHIBITORS FOR TREATING CANCER BIOMEDICAL RESEARCH FOUNDATION OF THE ACADEMY OF ATHENS (BRFAA) (GR) 2020-02-27 WO claimed
US-10287294-B2 Compounds for use in treating or preventing cancerous diseases BIOMEDICAL RESEARCH FOUNDATION OF THE ACADEMY OF ATHENS (GR) 2019-05-14 US claimed
US-20180208597-A1 NOVEL COMPOUNDS FOR USE IN TREATING OR PREVENTING CANCEROUS DISEASES BIOMEDICAL RESEARCH FOUNDATION OF THE ACADEMY OF ATHENS (GR) 2018-07-26 US claimed
EP-3319965-A1 NOVEL COMPOUNDS FOR USE IN TREATING OR PREVENTING CANCEROUS DISEASES Biomedical Research Foundation of the Academy of Athens (GR) 2018-05-16 EP claimed
WO-2017005919-A1 NOVEL COMPOUNDS FOR USE IN TREATING OR PREVENTING CANCEROUS DISEASES BIOMEDICAL RESEARCH FOUNDATION OF THE ACADEMY OF ATHENS (GR) 2017-01-12 WO claimed
WO-2015104292-A2 COMPOUNDS FOR USE IN TREATING OR PREVENTING CANCEROUS DISEASES BIOMEDICAL RESEARCH FOUNDATION OF THE ACADEMY OF ATHENS (GR) 2015-07-16 WO claimed
US-7897326-B2 Peroxisome-proliferator activated receptor-alpha agonists for organ preservation UNIVERSITY OF PITTSBURGH-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2011-03-01 US claimed
WO-2007106912-A2 PEROXISOME-PROLIFERATOR ACTIVATED RECEPTOR-ALPHA AGONISTS FOR ORGAN PRESERVATION UNIVERSITY OF PITTSBURGH OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2007-09-20 WO claimed
US-20070218451-A1 PEROXISOME-PROLIFERATOR ACTIVATED RECEPTOR-ALPHA AGONISTS FOR ORGAN PRESERVATION UNIVERSITY OF PITTSBURGH OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2007-09-20 US claimed
US-20040224995-A1 Neuroprotective effects of PPARy agonists against cellular oxidative insults UNIVERSITY OF NORTH TEXAS HEALTH SCIENCE CENTER AT FORT WORTH 2004-11-11 US claimed
US-RE37770-E1 SUCH AS LINOLEIC ACID, OLEIC ACID, 5,8,11,14-EICOSATETRAYNOIC ACID, 4-CHLORO-6-(2,3-XYLIDINO)-2-PYRIMIDINYL)THIOACETIC ACID, CLOFIBRATE, AND GEMFIBROZIL; USEFUL FOR TREATING DISORDERS OF EPIDERMAL DIFFERENTIATION AND PROLIFERATION. THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2002-06-25 US claimed
EP-3841097-B1 2,6-BIS(((1H-BENZO[D]IMIDAZOL-2-YL)THIO)METHYL)PYRIDINE AND N2,N6-DIBENZYLPYRIDINE-2,6-DICARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS PHOSPHOINOSITIDE 3-KINASE (PI3K) INHIBITORS FOR TREATING CANCER BIOMEDICAL RES FOUNDATION OF THE ACADEMY OF ATHENS BRFAA (GR) 2026-05-20 EP disclosed
EP-3319965-B1 NOVEL COMPOUNDS FOR USE IN TREATING OR PREVENTING CANCEROUS DISEASES BIOMEDICAL RES FOUNDATION OF THE ACADEMY OF ATHENS (GR) 2022-05-04 EP disclosed
US-6060515-A TOPICALLY APPLYING TO MAMMALIAN SKIN OR MUCOUS MEMBRANE A BARRIER DEVELOPMENT ENHANCING AMOUNT OF PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR ALPHA (PPARA) THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2000-05-09 US disclosed
WO-1998032444-A1 USE OF FXR, PPARα AND LXRα ACTIVATORS TO RESTORE BARRIER FUNCTION, PROMOTE EPIDERMAL DIFFERENTIATION AND INHIBIT PROLIFERATION THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 1998-07-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210246120-A1 METHOD OF PREPARATION AND USE OF PHOSPHOINOSITIDE 3-KINASE INHIBITORS IN TREATING CANCER PIK3R3, PIK3CA, PIK3C2A PPARA 3064/4885PPARG 1288/4885RXRA 4165/4885
US-20040224995-A1 Neuroprotective effects of PPARy agonists against cellular oxidative insults PPARG, PPARA, PPARD PPARA 2/4885PPARG 1/4885RXRA 112/4885
US-20180208597-A1 NOVEL COMPOUNDS FOR USE IN TREATING OR PREVENTING CANCEROUS DISEASES BRCA1, VHL, TSG101 PPARA 1247/4885PPARG 693/4885RXRA 1180/4885
US-10287294-B2 Compounds for use in treating or preventing cancerous diseases BRCA1, VHL, CYP27A1 PPARA 796/4885PPARG 535/4885RXRA 769/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.